$RCEL

Woody Joseph Fralin purchased $20K of RCEL

Woody Joseph Fralin purchased 5,000 shares of AVITA Medical, Inc. (RCEL) at $4.09 on 2026-06-03.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 5, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RCEL
Bullish
medium confidence
Mentioned
$RCEL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELBullishLow
01

Why it matters

The disclosure provides a new datapoint on insider ownership, but it does not include new clinical, regulatory, or financial developments that typically move the stock materially.

02

Market read

Use as a minor sentiment/positioning input; expect limited price impact absent other catalysts.

03

What to watch

Consider whether there were concurrent insider sales, broader volume/price moves around the same period, and upcoming company catalysts (trial updates, financing, or guidance) not mentioned here.

Relevance 6/10Novelty 6/10Timing: After-hours disclosure filed 2026-06-05 (Form 4) for a 2026-06-03 buy.

Background

The article summarizes an SEC Form 4 insider transaction for Avita Medical, Inc. (RCEL), showing an open-market purchase by a director.

Company-level read

Ticker impact

$RCELBullishMedium confidence
Context

Avita Medical director Woody Joseph Fralin bought 5,000 shares open-market at $4.0899 on 2026-06-03, disclosed via Form 4.

Expected impact

Likely limited/short-lived reaction; more useful as a sentiment/positioning signal than a driver.

Evidence & confidence

This is a routine Form 4 insider transaction with no accompanying new company-specific operational or financial information.

Market effects

No clear read-across to the broader biotech/medical device sector from a single director open-market buy.

None.

None.

Counterpoint

Insider buys can be driven by liquidity needs, diversification, or routine compensation/plan mechanics; this filing notes no 10b5-1 plan but still doesn’t confirm conviction.

Key entities

  • Avita Medical, Inc.

    RCEL, subject of the Form 4 insider purchase disclosure.

  • Woody Joseph Fralin

    Director who purchased 5,000 shares open-market; holdings after transaction: 92,761 shares.

Related articles

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

$RCELHighAI 9/10

Why is Avita Medical stock surging 20% today?

Avita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.

$RCELHigh

AVITA Medical, Inc. (RCEL): Results of Operations and Financial Condition

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a